These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 23459476)

  • 1. Characterization of porin expression in Klebsiella pneumoniae Carbapenemase (KPC)-producing K. pneumoniae identifies isolates most susceptible to the combination of colistin and carbapenems.
    Hong JH; Clancy CJ; Cheng S; Shields RK; Chen L; Doi Y; Zhao Y; Perlin DS; Kreiswirth BN; Nguyen MH
    Antimicrob Agents Chemother; 2013 May; 57(5):2147-53. PubMed ID: 23459476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations of the ompK36 porin gene and promoter impact responses of sequence type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin.
    Clancy CJ; Chen L; Hong JH; Cheng S; Hao B; Shields RK; Farrell AN; Doi Y; Zhao Y; Perlin DS; Kreiswirth BN; Nguyen MH
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5258-65. PubMed ID: 23939888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doripenem, gentamicin, and colistin, alone and in combinations, against gentamicin-susceptible, KPC-producing Klebsiella pneumoniae strains with various ompK36 genotypes.
    Clancy CJ; Hao B; Shields RK; Chen L; Perlin DS; Kreiswirth BN; Nguyen MH
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3521-5. PubMed ID: 24566172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae.
    Jernigan MG; Press EG; Nguyen MH; Clancy CJ; Shields RK
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3395-8. PubMed ID: 22430958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing Klebsiella pneumoniae may predict responses to carbapenem-colistin combination therapy among patients with bacteremia.
    Shields RK; Nguyen MH; Potoski BA; Press EG; Chen L; Kreiswirth BN; Clarke LG; Eschenauer GA; Clancy CJ
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1797-801. PubMed ID: 25534733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global survey of Klebsiella pneumoniae major porins from ertapenem non-susceptible isolates lacking carbapenemases.
    Wise MG; Horvath E; Young K; Sahm DF; Kazmierczak KM
    J Med Microbiol; 2018 Mar; 67(3):289-295. PubMed ID: 29458684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of OmpK36 to carbapenem susceptibility in KPC-producing Klebsiella pneumoniae.
    Landman D; Bratu S; Quale J
    J Med Microbiol; 2009 Oct; 58(Pt 10):1303-1308. PubMed ID: 19556371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic activity of colistin plus rifampin against colistin-resistant KPC-producing Klebsiella pneumoniae.
    Tascini C; Tagliaferri E; Giani T; Leonildi A; Flammini S; Casini B; Lewis R; Ferranti S; Rossolini GM; Menichetti F
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3990-3. PubMed ID: 23752510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outbreak caused by an ertapenem-resistant, CTX-M-15-producing Klebsiella pneumoniae sequence type 101 clone carrying an OmpK36 porin variant.
    Poulou A; Voulgari E; Vrioni G; Koumaki V; Xidopoulos G; Chatzipantazi V; Markou F; Tsakris A
    J Clin Microbiol; 2013 Oct; 51(10):3176-82. PubMed ID: 23850951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: the activity of the double-carbapenem regimen is related to meropenem MIC value.
    Oliva A; Scorzolini L; Cipolla A; Mascellino MT; Cancelli F; Castaldi D; D'Abramo A; D'Agostino C; Russo G; Ciardi MR; Mastroianni CM; Vullo V
    J Antimicrob Chemother; 2017 Jul; 72(7):1981-1984. PubMed ID: 28369424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the Genetic Background of KPC-2-Producing
    Wu LT; Guo MK; Ke SC; Lin YP; Pang YC; Nguyen HV; Chen CM
    Microb Drug Resist; 2020 Sep; 26(9):1050-1057. PubMed ID: 32283046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microbiological efficiency of the combinations of two carbapenems against antibiotic resistant Klebsiella pneumoniae strains.
    Tapalski DV; Timoshkova EV; Petrovskaya TA; Osipkina OV; Karpov IA
    Klin Lab Diagn; 2021 May; 66(5):304-309. PubMed ID: 34047517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro evaluation of dual carbapenem combinations against carbapenemase-producing Enterobacteriaceae.
    Poirel L; Kieffer N; Nordmann P
    J Antimicrob Chemother; 2016 Jan; 71(1):156-61. PubMed ID: 26416781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro evaluation of double carbapenem and colistin combinations against OXA-48, NDM carbapenemase-producing colistin-resistant Klebsiella pneumoniae strains.
    Erdem F; Abulaila A; Aktas Z; Oncul O
    Antimicrob Resist Infect Control; 2020 May; 9(1):70. PubMed ID: 32430058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of doripenem and ertapenem against KPC-2-producing and non-KPC-producing Klebsiella pneumoniae with similar MICs.
    Hagihara M; Crandon JL; Urban C; Nicolau DP
    J Antimicrob Chemother; 2013 Jul; 68(7):1616-8. PubMed ID: 23475648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Porins and bla
    Balabanian G; Rose M; Manning N; Landman D; Quale J
    Microb Drug Resist; 2018 Sep; 24(7):877-881. PubMed ID: 29782237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of association of OmpK35 and OmpK36 alteration and bla
    Hamzaoui Z; Ocampo-Sosa A; Fernandez Martinez M; Landolsi S; Ferjani S; Maamar E; Saidani M; Slim A; Martinez-Martinez L; Boutiba-Ben Boubaker I
    Int J Antimicrob Agents; 2018 Dec; 52(6):898-905. PubMed ID: 29621592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of β-lactamases and porin proteins OmpK35 and OmpK36 to carbapenem resistance in clinical isolates of KPC-2-producing Klebsiella pneumoniae.
    Zhang Y; Jiang X; Wang Y; Li G; Tian Y; Liu H; Ai F; Ma Y; Wang B; Ruan F; Rajakumar K
    Antimicrob Agents Chemother; 2014; 58(2):1214-7. PubMed ID: 24277031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of Ceftazidime-Avibactam Against Clinical Isolates of Klebsiella pneumoniae, Including KPC-Carrying Isolates, Endemic to New York City.
    Manning N; Balabanian G; Rose M; Landman D; Quale J
    Microb Drug Resist; 2018; 24(1):35-39. PubMed ID: 28590820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single or in combination antimicrobial resistance mechanisms of Klebsiella pneumoniae contribute to varied susceptibility to different carbapenems.
    Tsai YK; Liou CH; Fung CP; Lin JC; Siu LK
    PLoS One; 2013; 8(11):e79640. PubMed ID: 24265784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.